Search
SYN-101
go.drugbank.com/drugs/DB05958ExperimentalSYN101 is comprised of an immune cell specific antibody linked to an ALK5 inhibitor payload to selectively block TGF-b signalling in immune cells.
BMS-986141
go.drugbank.com/drugs/DB14942InvestigationalBMS-986141 is under investigation in clinical trial NCT02985632 (A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants).
V116517
go.drugbank.com/drugs/DB16060InvestigationalV116517 is under investigation in clinical trial NCT01688947 (Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)).
MEDI-547
go.drugbank.com/drugs/DB18360InvestigationalMEDI-547 is an anti-EphA1 monoclonal antibody conjugated to mcMMAF
Bacteriochlorophyll A
go.drugbank.com/drugs/DB01853ExperimentalA specific bacteriochlorophyll that is similar in structure to CHLOROPHYLL A.
Senlizumab
go.drugbank.com/drugs/DB17894ExperimentalSynonyms: BAY-10-3356Categories: Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-SteroidalIGN311
go.drugbank.com/drugs/DB04988ExperimentalIGN311 is a humanized monoclonal antibody (mab) against the Lewis Y carbohydrate antigen, a blood-group-related oligosaccharide.
SB-269970
go.drugbank.com/drugs/DB13988ExperimentalSB-269970 is an experimental drug developed by GlaxoSmithKline.
Prostaglandin D2
go.drugbank.com/drugs/DB02056ExperimentalIt is released upon activation of mast cells and is also synthesized by alveolar macrophages.
NSI-566
go.drugbank.com/drugs/DB17954InvestigationalDeveloped by Seneca Biopharma, it is being investigated for the treatment of amyotrophic lateral sclerosis (ALS), stroke, and chronic spinal cord injury (cSCI).[L47097]